Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03786081 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

A Phase 1 study of Cervical Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 1
Development phase
214
Enrollment target
20
Study locations

NCT03786081 is a Phase 1 study of Cervical Cancer that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 214 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03786081, a Phase 1 study of Cervical Cancer, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
214 participants
Enrollment target
20
Study locations

Study Summary

This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

Conditions Studied

Cervical Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Bevacizumab
  • DRUG Carboplatin
  • DRUG Tisotumab Vedotin

Study Locations (20)

Ohio

  • University of Cincinnati Physicians Group - Cincinnati
  • Cleveland Clinic - Cleveland
  • Cleveland Clinic - Cleveland
  • Ohio State University Wexner Medical Center - Hilliard

California

  • Univ California, Irvine Medical Center - Orange
  • Olive View - UCLA Research and Education Institute - Sylmar

Montana

  • Billings Clinic Cancer Center - Billings
  • Montana Cancer Consortium - Billings

New York

  • SUNY Downstate Medical Center - Brooklyn
  • Memorial Sloan Kettering Cancer Center - New York

Arizona

  • Arizona Oncology Associates - Phoenix

Florida

  • Baptist MD Anderson Cancer Center - Jacksonville

Georgia

  • Augusta University - Augusta

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 214 participants
Start Date 2019-02-27
Est. Completion 2026-03-31
Phase Phase 1

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03786081

The ClinicalTrials.gov registry entry for NCT03786081 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT03786081 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, California, Montana.

Frequently Asked Questions

What is clinical trial NCT03786081 about?

NCT03786081 is a clinical study titled "Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer". This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of ...

What is the current status of trial NCT03786081?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 214 participants. The study started on 2019-02-27. Estimated completion is 2026-03-31.

What conditions does trial NCT03786081 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT03786081?

The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Tisotumab Vedotin (DRUG).

Who is sponsoring clinical trial NCT03786081?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03786081 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.